You just read:

Boehringer Ingelheim and Duke Clinical Research Institute Expand Collaboration to Create Largest Patient Registry for Idiopathic Pulmonary Fibrosis (IPF)

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

25 Aug, 2016, 09:00 ET